Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

Olga Moser; Manuela Krumbholz; Christian Thiede; Josephine T. Tauer; Indra Janz; Melchior Lauten; Dagmar Dilloo; Markus Metzler; Meinolf Suttorp

doi:10.1002/pbc.25090

Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

Olga Moser, Manuela Krumbholz, Christian Thiede, Josephine T. Tauer, Indra Janz, Melchior Lauten^*, Dagmar Dilloo, Markus Metzler, Meinolf Suttorp

^*Corresponding author for this work

Department of Pediatric and Adolescent Medicine

8 Citations (Scopus)

Abstract

Approximately 40% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.

Original language	English
Journal	Pediatric Blood and Cancer
Volume	61
Issue number	11
Pages (from-to)	2080-2082
Number of pages	3
ISSN	1545-5009
DOIs	https://doi.org/10.1002/pbc.25090
Publication status	Published - 01.11.2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

Access to Document

10.1002/pbc.25090

Cite this

@article{09c3f0d4eb3941dcb499e39285b9f3cc,

title = "Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia",

abstract = "Approximately 40\% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.",

author = "Olga Moser and Manuela Krumbholz and Christian Thiede and Tauer, \{Josephine T.\} and Indra Janz and Melchior Lauten and Dagmar Dilloo and Markus Metzler and Meinolf Suttorp",

year = "2014",

month = nov,

day = "1",

doi = "10.1002/pbc.25090",

language = "English",

volume = "61",

pages = "2080--2082",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "11",

}

TY - JOUR

T1 - Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

AU - Moser, Olga

AU - Krumbholz, Manuela

AU - Thiede, Christian

AU - Tauer, Josephine T.

AU - Janz, Indra

AU - Lauten, Melchior

AU - Dilloo, Dagmar

AU - Metzler, Markus

AU - Suttorp, Meinolf

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Approximately 40% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.

AB - Approximately 40% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.

UR - https://www.scopus.com/pages/publications/84915736394

U2 - 10.1002/pbc.25090

DO - 10.1002/pbc.25090

M3 - Journal articles

C2 - 24810322

AN - SCOPUS:84915736394

SN - 1545-5009

VL - 61

SP - 2080

EP - 2082

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 11

ER -

Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

Abstract

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this